Dr. Dominic D’Agostino holds a PhD in neuroscience and physiology from the University of Medicine and Dentistry of New Jersey. Focusing on areas like ketone supplementation and ketone technologies, Dr. Dominic D’Agostino is currently an associate professor at the University of South Florida College of Medicine’s molecular pharmacology and physiology department. He is also a research scientist at the Institute for Human and Machine Cognition (IHMC).
Dr. Angela Poff, a research associate from the same department at USF, recently commented on studies to cover the science supporting the ketogenic diet as an adjuvant treatment for breast cancer. Dr. Poff discussed that since tumor cells rely primarily on glucose and glutamine, a low-carbohydrate diet keto diet may indeed deprive the cancer of its preferred source of fuel, also emphasizing the suppression of insulin signaling. She also emphasized, however, that further ketone research is needed to fully understand the cancer-suppressing characteristics of this diet. The preclinical work is compelling, but human clinical trials are needed.
The ketogenic diet is a low-carb diet that places the body under the metabolic state of nutritional ketosis. Carbohydrate restriction shifts the body’s metabolic physiology from a carbohydrate and glucose dependent metabolism to a fat and ketone-based metabolism. This process also suppresses may of the signaling factors that are driving the growth and proliferation of cancer.
According to studies, particularly one by Professor Thomas Seyfried of Boston College, the ketogenic diet may be capable of revolutionizing the treatment of breast cancer, even contending that cancer can be investigated as a metabolic disease rather than a genetic one. Evidence supporting the theory of cancer as a metabolic disease has major implication on how we treat and prevent cancer. It is likely that metabolic-based approaches will also synergize with other mof=dalities and further augment the cancer-killing effects of radiation, chemotherapy and newly evolving immune-based therapies.